Neuroscience Letters Publishes Peer-Reviewed Study on Rexahn Pharmaceuticals (RNN) Drug Candidate
Rexahn Pharmaceuticals, Inc. announced today the publication of a peer-reviewed study in Neuroscience Letters. The study validates the mechanism of clavulanic acid, the active compound in Serdaxin®, the company’s lead CNS drug. The published study, entitled “Clavulanic acid increases dopamine release in neuronal cells through a mechanism involving enhanced vesicle trafficking,” shows that clavulanic acid enhances release of neurotransmitters such as dopamine in the brain cell by interacting with key proteins for vesicle trafficking and fusion. “This study is significant because it confirms at the molecular and cellular levels how Serdaxin enhances the release of neurotransmitters in the brain. Previous…